Skip to main content

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content

Review patient stories about TYVASO

arrow left for videos arrow right for videos

“Taking my TYVASO DPI has become very routine. It’s something that’s very simple for me.”

Hear more about how TYVASO DPI fits into Kirsten’s day-to-day life.

Kirsten’s experience with TYVASO DPI

Sally’s journey starting TYVASO DPI

Catherine’s switch to TYVASO DPI

Catherine’s nebulizer story

Tina’s experience on TYVASO

Review patient stories about TYVASO

“Taking my TYVASO DPI has become very routine. It’s something that’s very simple for me.”

Hear more about how TYVASO DPI fits into Kirsten’s day-to-day life.

“At that point, I knew this medication was working for me.”

Hear more about Sally's experience living with PH-ILD and getting started on TYVASO DPI.

“I'm able to participate in more family activities.”

Get an update on Catherine’s journey switching to TYVASO DPI.

“I adapted to using TYVASO very quickly and easily. It's just become part of my normal routine.”

Hear about Catherine’s journey getting started on the TYVASO nebulizer.

“After a few weeks, I felt like I had deeper breaths, and I could walk further.”

Hear from Tina about her experience with titration using the TYVASO nebulizer.

DPI=dry powder inhaler.